Swiss regulators investigate Novartis over 'unlawful abuse' of dermatology patent
Novartis is being investigated by an antitrust watchdog for asserting a patent, although the company says it stands by its move.
Regulators at the Swiss Competition Commission paid a visit to Novartis’ headquarters in Basel, the Swiss pharma giant disclosed in a terse statement.
Like many big players with lucrative portfolios to defend, Novartis has been no stranger to patent disputes — and it’s been on all sides of those spats, whether it’s trying to block generics from entering the market, being sued for infringement or getting in trouble for alleged pay-for-delay schemes.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.